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Abstract  Objective: To observe triple negative breast cancer (TNBC) characteristics in 
three hospitals located in Bandung based on basal-like (BL) and non-basal-
like (NBL) subtypes.   Methods: This was a cross-sectional study which used descriptive categorical 
data from medical records and paraffin blocks of TNBC patients treated in Dr. 
Hasan Sadikin General Hospital, Bandung; Borromeus Hospital; and Santosa 
Hospital Bandung Central in the period of January 1, 2012–December 31, 
2016. The subjects of the study were 57 TNBC patients. The data collected in 
the study based on medical records were age, tumor size, histopathological 
images, severity, and immunohistochemical data. The paraffin blocks of the 
patients based on the completed medicals records were investigated through 
examinations of immunohistochemichal cytokeratin (CK) 5/6 expressions 
and epidermal growth factor receptor (EGFR).  Results: Prevalence of TNBC were 82.5% of basal-like subjects and 17.5% 
of non-basal-like subjects. Among the TNBC subjects, median age of each 
subtype was 50 years of basal-like subtype and 45 years of non-basal-like 
subtype. Both subtypes were mostly found in the subjects who aged >40 years. 
Higher histopathological grade was discovered in both subtypes. The therapy 
mostly carried out to the subjects was adjuvant chemotherapy. Majority of 
basal-like subtype subjects were still alive and had longer survival rate and 
lower incidences of deaths when compared to the non-basal-like subtype.  Conclusions: In TNBC, the basal-like subjects showed greater median age, 
lower severity stage, and longer survival rate than the non-basal-like subjects. 
There was no histopathology grade between both subtypes. 
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IntroductionBreast cancer (BC) is considered as one of 
many cancers mostly found in Indonesian 
people. Incidences of females with BC in 
Indonesia were approximately 12/100,000 
females while in United States 92/100,000 females suffering from BC leading to a large 
number of mortalities of 27/100.000 or 18% 
deaths. However, a study stated that in male 
population there may be 1% of them.1 Breast 
cancer is characteristically a heterogenous 
disease consisting of numerous subtypes with 
distinctive disease history. It represents large spectrum based on clinical, pathological, and mulecular images and has various prognostic 
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Molecular classification of breast cancer can be distinguished into several groups based 
on gene expression images by using modest 
technology of microarray deoxyribonucleic 
acid (DNA). From gene expression images, BC 
is classified into 5 subtypes: luminal A, luminal 
B, triple negative or basal-like, normal like, 
and excessive human epidermal growth factor 
receptor 2 (HER2).3
The molecular subtypes are commonly 
associated with survival rate: luminal A tumor has favourable prognosis and normal-
like tumor has moderate prognosis.  Luminal 
B, HER2 positive, and basal-like tumors are 
commonly associated with shorter relapse-
free survival (RFS) and overall survival 
(OS). The molecular subtypes can predict 
therapy response; HER2 positive and basal-
like tumors show greater complete response 
(CR) after neoadjuvant chemotherapy when 
compared to luminal and normal-like tumors.4 
Triple negative is also known as breast 
cancer subtypes with estrogen receptor (ER) 
negative, progresteron receptor (PR) negative, 
and lower HER2. The triple negative breast 
cancer (TNBC) has represented 15–12% of 
newly BC incidences. It has epidemiological, 
hispathological, and clinical image which 
are different from other BC subtypes.5 It 
also shows characteristics of more agressive clinical behavior, particular metastasis images, 
and worse prognosis. The focus is on the TNBC 
is due to the limitations of the therapy. Until 
today, the only therapy for TNBC patients is 
systemic chemotherapy.6  
In many incidences the TNBC is categorized 
as basal-like BC. On the contrary, several 
studies revealed that TNBC and basal-like BC 
are biologically different tumors. There were 
many TNBC incidences which could not be 
identified as basal-like (nearly 80%) and there 
were basal-like tumors which could not be determined as TNBC.7 A previous study in 2013 
stated that TNBC is a wide subject with various 
categories so that additional subclassifications is then required.8 
Gene expression profile (GEP) examination 
divides TNBC into seven molecular subtypes 
i.e. basal-like 1, basal-like 2, mesenchymal 
(M), mesenchymal stem cell like (MSL), 
immunomodulatory (IM), luminal androgen 
receptor (AR)-like (LAR), and unknown 
classification (UNC).9 The classification based 
on these subtypes can cause distinctive 
response during the therapy perceived by each patient.10 The gene expression profile examination becomes a non-practical medical 
tool which is regularly conducted in the 
hospitals due to the expensive costs. Pratt et 
al.8 suggested that a study on TNBC can be 
conducted by classifying the subjects based on 
basal-like tumor versus non-basal-like tumor. Neilsen et al.6 proposed immunohistochemical 
examination can be used to substitute GEP 
examination in order to identify BC of basal-like 
subtype which has the same definition as cDNA 
microarray examinations such as ER- HER-2- 
and CK 5/6 or EGFR+. Immunohistochemical 
examination can illustrate sensitivity (76%) 
and specifity (100%) in identifying BC of basal-
like subtype such as fenotype basal obtained 
through GEP examination.
The TNBC of basal-like subtype has the same morphological characteristics as the higher 
histopathology grade. The majority incidences 
found in TNBC of basal-like subtype were 
commonly associated with disease history, locoregional disease development, and more 
agressive metastasis in the first 5 year. This condition can cause shorter survival rate and higher mortalities.  
A previous study revealed that TNBC of 
basal-like subtype becomes an independent 
marker so that BC can have worse prognosis 
as commonly found in cancer with or without 
lymph node metastasis. Tumor with basal-like 
fenotipe is a worse predictor for the patients 
such as histopathology grade 3, tumor without 
lymph node metastasis, and the patients 
with severe metastasis. The Basal-like tumor determines that metastasis can occur in the 
brain and lung but metastasis rarely occurs in the bone or liver.7
There is another finding of various biological 
terms from TNBC which is applicable to spread 
knowledge regarding to effective systemical 
therapy, provide newly medication including 
immune checkpoint inhibitor, poly (ADP 
ribose) polymerase (PARP) inhibitor, cytotoxic 
therapy including platinum chemoherapy 
medication, phosphatidylinositol-3 kinase 
pathway inhibitors, and androgen receptor 
(AR)  inhibitor.10 Therefore, this study aimed to investigate TNBC characteristics based on 
basal-like and nonbasal-like subtypes in three hospitals in Bandung.
Methods
Target population in this study was TNBC 
patients but the population included was 
carcinoma TNBC patients who had been treated in the three hospitals in Bandung, West Java, 
Indonesia such as Dr. Hasan Sadikin General Hospital, Bandung, Borromeus Hospital, and 
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Santosa Hospital Bandung Central, Indonesia 
in the period of January 1 2012–December 31 
2016. The study used cross-sectional method 
with descriptive categorical design.  Samples 
were the population which met the inclusion criteria.
The inclusion criteria in the study were 
BC patients who histopathologically and immunohistochemical diagnosed suffering 
from TNBC carcinoma; slices of paraffin blocks 
with routine stain of Hematoxylin-eosin, ER-, 
PR-, dan HER-2- which could be examined; 
tissue of block paraffin could be evaluated 
through HE stain or immunohistochemical 
CK 5/6 and EGFR; the data in the medical records of TNBC patients consisted of age, 
severity, tumore grading, chemotherapy types, 
and chemotherapy response; tissue handling 
was performed based on the standard by 
using neutral buffer formalin. Exclusion 
criteria were the patients who had given 
chemotherapy before histopathological and 
immunohistochemical examinations while TNBC treatments. 
The TNBC patients in the study were 
treated which were based on histopathological 
examinations from breast biopsy via 
immunohistochemical examinations ER(-), 
PR(-), HER2(-). The immunohistochemical 
examinations determined that the ER or PR 
would be negative if the result was <1% while 
the HER-2 would be negative if the result 
was <+1. The immunoexpressions of CK 5/6 
and EGFR were presented in percentage as 
the cell which expressed CK 5/6 and EGFR from the total tumor cells in representative 
areas. The CK 5/6 and EGFR assessments 
were calculated by using histoscore obtained through immunohistochemical examinations 
consisting of two positive values of qualitative calculations and distribution positive values in several quantitative calculations. 
Nevertheless, this study could be considered 
as a semiquantitative study.
The positive values of CK 5/6 and EGFR 
were obtained from the brown color of BC 
cytoplasm cells observed by using light 
microscope which can be classified into 4 
levels: 0 (negative) represented color intensity 
was the same as negative control which is not in 
brown color; 1 (low positive) was light brown 
color; 2 (moderate positive) was brown color; 
3 (strong positive) was dark color which was 
the same color intensity as positive control. The positive values of tumor cells are quantitative values in the form of percentage of 
brown color intensity distribution per field of 
view based on the examinations by using light 
microscope by magnifications of 400 times. 
The values were categorized into 5 levels: 0 
(negative); 1 (<25% if the tumor cells were in 
brown color); 2 (25–<50% if the tumor cells 
were brown color); 3 (50–75% if the tumor 
cells were brown color); 4 (>75% if the tumor 
cells were brown color).
Both values obtained were distributions of 
intensity and positivity. Then, the intensity had 
been timed to positivity due to discover the 
final value which was regarded as histoscore 
(HS). This value was determined based on 
immunoreactive scoring system (IRS) by 
Remmele W. and Stegner H. E. Negative 
immunoexpression would be negative if 
the histoscore was <4 (0–3) and it would be 
positive if the histoscore was >4 (4–12) .11Histoscore= = i x d
There are associations between cancers 
with the treatments and examinations. The 
TNBC of basal-like can be diagnosed via 
immunochemical examination of CK 5/6 (+) 
and EGFR (+), or CK 5/6 (-) and EGFR (+), or 
CK 5/6 (+) and EGFR (-). The TNBC non-basal-
like can be examined by using examinations of 
immunochemical CK 5/6 (-) and EGFR (-). 
Neoadjuvant is a chemotherapy which is 
given before surgery.12 Adjuvant chemotherapy 
is commonly carried out after surgery. While 
palliative chemotherapy is given to BC which has been metastased.12 
Neoadjuvant chemotherapy response are determined as clinical response based on response evaluation criteria in solid tumors 
(RECIST) with revision version of 1.1 year 
2009. The patients may have response if the 
condition meets complete response (CR) 
criteria and partial response (PR) but the response does not meet the criteria if the conditions represent progressive disease (PD) and stable disease (SD).13
Response of adjuvant chemotherapy in 
this study was not asssessed based on RECIST because BC mass had been resected. Palliative 
chemotherapy response was diagnosed by 
using clinical response based on RECIST. The patients could have response if the condition 
met the CR, PR, and SD while no response was discovered if the condition met the criteria of PD.13
The data in this study were collected 
by discovering paraffin blocks, recording 
pathology anatomy, numbers and medica 
records’ numbers from the biopsy specimens of the TNBC patients at the Department of 
Pathology Anatomy, Dr. Hasan Sadikin General 
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Hospital, Bandung; Borromeus Hospital; and 
Santosa Hospital Bandung Central. Afterwards, 
the data of medical records were synchronized based on the data stored at the three hospitals. 
If the paraffin blocks were available and still in 
proper condition, the paraffin blocks would be observed relating to the immunohistochemical 
expressions of CK 5/6 and EGFR at the 
laboratory of the Department of Pathology 
Anatomy, Dr. Hasan Sadikin General Hospital, Bandung.
Results 
This study was initiated to investigate the 
TNBC characteristics based on basal-like and 
non-basal-like subtypes during March 2017 
to November 2017. Population in the study 
was TNBC patients who were treated in Dr. 
Hasan Sadikin General Hospital, Bandung; Borromeus Hospital; and Santosa Hospital 
Bandung Central in the period of January to December 2016.
Among the samples, only 57 samples were 
included in the study as the subjects. The study 
could be regarded as the first study which 
divided TNBC into basal-like and non-basal-
like in Bandung, Indonesia.
Among the subjects, fourty seven subjects 
had TNBC through CK5/6 and EGFR (basal-
like subtype) examinations while 10 subjects 
were observed by using expressions of 
immunohistochemical CK 5/6 negative and 
EGFR negative (nonbasal-like subtype) (Table 1).
Adjuvant chemotherapy were mostly 
given to the subjects in the study (32 out of 
57 subjects). The adjuvant chemotherapy 
commonly given to the subjects combination 
of were doxorubicin and cyclophosphamide (Table 2).
Neoadjuvant chemotherapy was given to 
4 TNBC of basal-like subtype subjects. The 
results revealed that the response showed 
partial response (PaR), the tumor shrinked 
>30% after neoadjuvant chemotherapy. 
Additionally, all the subjects were given 
neoadjuvant chemotherapy with surgery and 
adjuvant chemotherapy. 
Neoadjuvant chemotherapy was also given 
to a subject with non-basal-like with PaR then 
the subject was given surgery and adjuvant 
chemotherapy. After six months, metastasis occurred in the lung and brain and the subject died one month later. 






Age (yrs.)Mean (SD) 50 ± 11 45 ± 13
Range 30 – 75 23 – 68
Age group (yrs.)
<40 10 (21.3) 3 (30.0)
>40 37 (78.7) 7 (70.0)
Tumor size (cm)
≤2 10 (21.3) 2 (20.0)
2.1–5 23 (48.9) 2 (20.0)
>5 14 (29.8) 6 (60.0)Tumor necrosis
Existed 14 (29.8) 3 (30.0)None 30 (63.9) 6 (60.0)No data 3 (6.3) 1 (10.0)
Lymphocyte 
infiltration
Existed 24 (51.1) 2 (20.0)None 20 (42.6) 7 (70.0)No data 3(6.3) 1 (10.0)
Lymphovascular invasion
Existed 26 (55.3) 7 (70.0)None 21 (44.7) 3(30.0)
Histopathology grade
Grade 1 2 (4.3) 0 (0.0)
Grade 2 18 (38.3) 3 (30.0)
Grade 3 23 (48.9) 5 (50.0)No data 4 (8.5) 2(20.0)
Lymp node metastasisNone 18 (38.3) 5 (50.0)
1–3 15 (31.9) 0 (0.0)
≥4 11 (23.4) 5 (50.0)No data 3(6.4) 0(0.0)Tumor stageI 4(8.5) 1 (10.0)
Basic Characteristics of the 
Subjects Based on Triple Negative 
Breast Cancer between Basal-like 
and Non-basal- like Subtypes
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Palliative chemotherapy was given to 3 
TNBC subjects. Among the 2 subjects with 
basal-like, 1 subject who was given palliative 
chemotherapy had lung metastasis and 
showed response after SD chemotherapy. 
Palliative chemotherapy was carried out to a 
TNBC of non-basal-like subject with liver and 
bone metastases and showed response after 
SD chemotherapy.
More than a half of TNBC of basal-like 
subtype subjects were still alive, 20% of non-
basal-like subtype subjects were alive, and 
30% of the subjects died. However, a half of 
TNBC of non-basal-like subtype subjects until 
October 2017 relating to their status were still 
unknown (Table 3). Mean alive of the TNBC 
of basal-like subtype subjects had 7 months 
more of prolonged life when compared to the 
non-basal-like subtype.
Discussion
Prevalences of TNBC of basal-like subtype in 
this study were 82.5% (47 out of 57 subjects) 
while prevalences of TNBC non-basal-like 
subtype were 17.5% (10 out of 57 subjects). 
The results were in accordance with a previous 
study included GEP examination reported 
that 70–80% TNBC subjects were basal-like 
subtype and 20–30% subjects were non-
basal-like subtype.9 The GEP examination in 
BC can distinguish intrinsic subtype which has 
significant prognostic and predicative value 
but it is uneasily performed in daily clinical examination. The immunohistochemical is 
affordable for daily clinical examinations 
due to identify protein expression as a 
marker of TNBC of basal-like gene. The immunohistochemical examination is suitable 
to detect TNBC of basal-like (cytokeratin 
CK5/6 and or EGFR positive, ER negative, and 
HER2 negative) which has 76% sensitivity 
and 100% specifity.4 The TNBC of basal-like 
subtype has different molecular lesion (p53 
stabilization and more indication of mitosis) 
and is associated with lower level of survival 
rate when compared to the non-basal-like 
subtype.4,9
Mean age of TNBC of basal-like subtype 
in this study was 50 years (ranged 30–75) 
which lower than the non-basal-like subtype 
(45 years ranged 23–68). A study by Fadare and Tavassoli revealed that mean age of basal-
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II 21 (44.7) 3 (30.0)III 18 (38.3) 4(40.0)IV 4 (8.5) 2 (20.0)
Histopathology 
typesInvasive ductal carcinoma mammae (IDCM) 
/ invasive carcinoma mammae non 
specified type
38 (80.9) 8(80.0)
Metaplastic carcinoma mammae 3 (6.4) 0 (0.0)Invasive lobular carcinoma mammae 
(ILCM)/ ILCM 
plemorphic type
3 (6.4) 0 (0.0)
Mucoid carcinoma mammae 0 (0.0) 1 (10.0)
Secretory carcinoma mammae 1 (2.1) 0 (0.0)
Mixed IDCM+ 
medulary 1 (2.1) 0 (0.0)
Mixed IDCM+ mucoid carcinoma  mammae 0 (0.0) 1 (10.0)
Mixed IDCM + Paget Disease 1 (2.1) 0 (0.0)
Type of 
chemotherapy Neoadjuvant 4 (8.5) 1 (10.0)
Adjuvant 29 (63.8) 3 (40.0)Palliative 2 (8.5) 1 (10.0)No 
chemotherapy 5 (6.4) 0 (0.0)No data 7 (12.8) 5 (40.0)Ki-67
<20% 17 (36.2) 8 (80.0)
≥20% 21 (44.7) 0 (0.0)Without assessment 9 (19.1) 2 (20.0)
P53Negative 12 (25.5) 5 (50.0)Positive 14 (29.8) 4 (40.0)
Without assessment 21 (44.7) 1 (10.0)
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like subtype subjects was 47.7–55 while mean 
age of analyses by using GEP examination 
was 54.14 Another previous study stated that 
tumor with greater basal was mostly found 
in 40–50 years.2 There is still unclear finding 
that TNBC of basal-like subtype subjects are 
younger than the non-basal-like subtype 
subjects because many related previous studies have different results.14 The basal-like 
subtype have significantly younger mean age 
when compared to non-basal-like subtype 
subjects. In contrary, Polish Breast Cancer 
Study (804 subjects) and Nurses’s Health 
Study (872 subjects) reported that there was 
no difference age between TNBC of basal-like 
and non-basal-like subtypes.14
The TNBC of basal-like subtype was mostly 
found in subjects who were in stage II while 
non-basal-like subtype was mostly found in 
stage III. The stage IV of TNBC of basal-like 
subjects in this study had metastases in the 
lung, bone, and liver while metastases in the 
liver and bone were found in the non-basal-
like subjects. This finding is different from a 
cohort study in Japan which described that 
TNBC basal-like subtype had brain and lung 
metastases. Another study confirmed that 
TNBC of basal-like subtype and TNBC which 
has relation to BRCA1 mutation which has 
metastasis in the brain. The TNBC of basal-like 
had lower metastases in the bone and liver 
when compared to ductal carcinoma of stage 
III non-basal-like subtype.14
There is no histopathology different type in 
both basal-like and non-basal-like subtypes in 
this study is invasive ductal carcinoma. This is 
suitable with a study in morphological basal-
like subtype with GEP, 21 out 23 patients 
(91%) was ductal carcinoma. Several studies 
with immunohistochemical examination also 
supported that ductal cancer is the mostly 
histological TNBC of basal-like subtype. If 
the analyses were focused on the ER- tumor 
group, the data would show that 80% of both 
TNBC of nonbasal-like and basal-like subtypes are considered as ductal carcinoma or combination of ductal carcinoma and another 
hisopathology types.Beside invasive ductal carcinoma mammae 
histopathology, other histopathologies can 
be found in basal-like subtype subjects such as carcinoma metaplastic, invasive lobular 
carcinoma mammae pleomorphic type, 
secretory carcinoma mammae, medullary, 
dan Paget disesase. Among histopathologies, 
mucoid carcinoma mammae was frequently 
found in non-basal-like subtype subjects. This 
finding is similar to a previous study which 
stated that histopatologies such as medullary carcinoma or combination of ductal carcinoma 
and medullary carcinoma represents basal-
like phenotype. 
Table 2
Chemotherapy Types Responses Basal-like n=36
Non-basal-like 
n=5Neoadjuvant Response (CR, PaR) 4 1No respon (SD, PD) 0 0Cannot be assessed 0 0
Adjuvant Cannot be assessed 30 3Palliative Response (CR, PaR, SD 1 1
No Response (PD) 1 0Cannot be assessed 0 0
Characteristic of Chemotherapy Response of Triple Negative Breast Cancer of 
Basal-like and Non-basal- like Subtypes Based on Chemotherapy Types
Table 3
Last Condition Basal-like n=47 (%)
Non-basal-
like n=10(%)
Alive 25 (53.2) 2 (20.0)Dead 13 (27.7) 3 (30.0)
Unknown 9 (19.1) 5 (50.0)
Characteristics of the Last 
Condition between Triple Negative 
Breast Cancer of Basal-like and 
Non-basal-like Subtypes
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In summary, TNBC in the hospitals in 
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of TNBC of basal-like subtypes were higher than another one. Mean age of TNBC basal-
like was higher than non-basal-like. There was 
no different type and degree of hispathology 
found in both subtypes. More severe BC was 
discovered in non-basal-like subtype. The 
theraphy commonly given to the subjects of 
both subtypes was adjuvant chemotherapy so 
that the chemotherapy response was hardly 
discovered in this study. Among the subjects, 
deaths in this study were mostly found in 
TNBC of non-basal subtype when compared to 
the basal-like subjects.
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